ITI-333 is under clinical development by Intra-Cellular Therapies and currently in Phase I for Depression. According to GlobalData, Phase I drugs for Depression have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ITI-333’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITI-333 overview
ITI-333 is under development for the treatment of opioid use disorder, pain and mood disorders (depression and anxiety). It is administered through oral route as a solution. The drug candidate acts by targeting D1A dopamine receptor, Mu type opioid receptor, serotonin 5-HT2A receptor. It is developed based on CNSProfile platform.
Intra-Cellular Therapies overview
Intra-Cellular Therapies (ICTI) is a biopharmaceutical company that discovers and developed and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders. The compnay pipeline includes lumateperone for the treatment of the major depressive disorder and bipolar depression and TI-1284-ODT-SL for the treatment of agitation and psychosis in patients with Alzheimer’s. ICTI’s other pipeline includes PDE inhibitor for Parkinson’s and cancer immunotherapy and ITI-333 for opioid use disorder, pain and mood disorders. It also utilizes CNSProfile, a technology platform that monitors the phosphoprotein changes elicited by major psychotropic drug classes and subclasses and generates a unique molecular signature for drug compounds. ICTI is headquartered in New York, the US.
For a complete picture of ITI-333’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
